Temperature‐controlled radiofrequency ablation for the treatment of chronic rhinitis: Two‐year outcomes from a prospective multicenter trial

Masayoshi Takashima,J. Pablo Stolovitzky,Randall A. Ow,Stacey L. Silvers,Chad M. McDuffie,Marc Dean,Ahmad R. Sedaghat,Bobby A. Tajudeen
DOI: https://doi.org/10.1002/alr.23315
2024-01-26
International Forum of Allergy & Rhinology
Abstract:Background Minimally invasive temperature‐controlled radiofrequency (TCRF) ablation of the posterior nasal nerve (PNN) demonstrated a significant larger treatment effect on the symptom burden of chronic rhinitis patients than a sham control (no energy delivery) at the 3‐month primary endpoint of this trial. Methods Two‐year posttreatment outcomes for patients treated in a prospective, multicenter, patient‐blinded randomized controlled trial were determined by combining the index active treatment‐arm and index control‐arm crossover patients into a single group (after the primary endpoint) to evaluate the treatment effect durability and long‐term effects on concomitant chronic rhinitis medication usage. Results The mean baseline reflective total nasal symptom score (rTNSS) was 8.2 (95% confidence interval [CI], 7.9–8.6; N = 104). At 2 years (N = 79), the mean change in rTNSS was −5.3 (95% CI, −5.8 to −4.8; p
otorhinolaryngology
What problem does this paper attempt to address?